Comparison of cinoxacin and trimethoprim-sulfamethoxazole in the treatment of urinary tract infections.
Forty women with uncomplicated urinary tract infections owing to susceptible organisms were assigned randomly to 500 mg. cinoxacin or 160--800 mg. trimethoprim-sulfamethoxazole twice daily for 10 days. Of 20 patients receiving cinoxacin none had bacteriuria during or 7 days after therapy, and 2 of 15 (13 per cent) were reinfected within 30 days. Of 20 patients receiving trimethoprim-sulfamethoxazole 1 (5 per cent) had bacteriuria during therapy, 19 were uninfected during and 7 days after therapy, and 3 of 15 (20 per cent) were reinfected within 30 days. Adverse reactions occurred in 2 patients (10 per cent) in each group. Anal and vaginal Enterobacteriaceae maintained their sensitivity to cinoxacin. Three patients (20 per cent) on trimethoprim-sulfamethoxazole presented with and 3 acquired anal Enterobacteriaceae resistant to the drug and 2 (13 per cent) acquired vaginal Enterobacteriaceae that were resistant. Cinoxacin was as effective as trimethoprim-sulfamethoxazole without the emergence of resistant bacteria associated with trimethoprim-sulfamethoxazole.
D000328:Adult; D002937:Cinoxacin / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D004351:Drug Resistance; D004755:Enterobacteriaceae / Q000187:drug effects; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D005243:Feces / Q000382:microbiology; D005260:Female; D006801:Humans; D011724:Pyridazines / Q000627:therapeutic use*; D012008:Recurrence; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000652:urine; D014621:Vagina / Q000382:microbiology
D004338:Drug Combinations; D011724:Pyridazines; D014295:Trimethoprim; D013420:Sulfamethoxazole; D002937:Cinoxacin